Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment
US12171820B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 13, 2020 |
| Grant date | Dec 24, 2024 |
| Priority date | — |
| Expiry date | Oct 1, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/515
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention pertains to engineered immune cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered immune cells of the present invention are characterized in that at least one gene selected from a gene encoding GCN2 and a gene encoding PRDM1 is inactivated or repressed. Such modified Immune cells are resistant to an arginine and/or tryptophan depleted microenvironment caused by, e.g., tumor cells, which makes the immune cells of the invention particularly suitable for immunotherapy. The invention opens the way to standard and affordable adoptive immunotherapy strategies using immune cells for treating different types of malignancies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.